Orteronel Leaves Hole In Millennium/Takeda Pipeline
This article was originally published in PharmAsia News
The non-steroidal androgen synthesis inhibitor failed to show a survival benefit in chemotherapy-naïve prostate cancer patients after also failing in post-chemo patients in 2013. With Takeda ending development of the Phase III candidate, its Millennium cancer pipeline is reduced to a pair of Phase III candidates.
You may also be interested in...
Nearly a decade after entering the oncology field, Bayer has three products on the market, two candidates in Phase II trials and a dozen more in Phase I trials; at ASCO it will talk to a potential partner about a combination drug study.
In an interview with “The Pink Sheet” at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business and of the key late-stage assets that will carry the company into the next decade.
Phase III ELM-PC 5 study of orteronel in post-chemo metastatic castration-resistant prostate cancer is unblinded after drug fails to improve overall survival. But the company is continuing a Phase III trial in an earlier line of therapy.